FIGURE LEGENDS

Figure 1. CXCL13 levels in neuroinflammatory conditions.

CXCL13 levels in A) CSF and B) serum in subjects with multiple sclerosis (MS), neuromyelitis optica (NMO), other inflammatory neurological conditions (OIC), and noninflammatory controls (NIC). CXCL13 correlates with C) IgG index and D) white blood cell count (WBC) across patient groups (solid lines) although correlations are still seen for IgG index in MS subjects (C) and WBC for NMO subjects (D)(dashed lines represent subgroup correlations of interest). Disability, as assessed using the expanded disability status scale (EDSS), correlated with E) CSF neurofilament and F) CSF CXCL13. Note that logarithmic scales were used to better demonstrate values.

eFigure 1

eFigure 1. CSF biomarker in neuroinflammatory conditions.

A) CSF neurofilament (NF) and D) myelin basic protein (MBP) in subjects with multiple sclerosis (MS), neuromyelitis optica (NMO), other inflammatory neurological conditions (OIC), and noninflammatory controls (NIC). Medians are indicated. CXCL13 correlates with C) CSF protein and D) number of oligoclonal bands (OCB) across patient groups (solid lines). Disability, as assessed using the expanded disability status scale (EDSS), correlated with E) CSF protein and F) number of white blood cells (WBC). Note that logarithmic scales were sometimes used to better demonstrate values.

eFigure 2. Biomarker correlations.

Correlations between A) CXCL13 in CSF and serum, B) CSF CXL13 and CSF neurofilament (NF), C) CSF myelin basic protein (MBP) and NF, and D) CSF CXCL13 and MBP in subjects with MS, neuromyelitis optica (NMO), other inflammatory conditions (OIC), and noninflammatory controls (NIC). No correlations were found between CSF CXCL13 and serum CXCL13 (A) or MBP (D).



eFigure 1. CSF biomarker in neuroinflammatory conditions.
A) CSF neurofilament (NF) and D) myelin basic protein (MBP) in subjects with multiple sclerosis (MS), neuromyelitis optica (NMO), other inflammatory neurological conditions (OIC), and noninflammatory controls (NIC). Medians are indicated. CXCL13 correlates with C) CSF protein and D) number of oligoclonal bands (OCB) across patient groups (solid lines). Disability, as assessed using the expanded disability status scale (EDSS), correlated with E) CSF protein and F) number of white blood cells (WBC). Note that logarithmic scales were sometimes used to better demonstrate values.

254x381mm (96 x 96 DPI)



eFigure 2. Biomarker correlations.
Correlations between A) CXCL13 in CSF and serum, B) CSF CXL13 and CSF neurofilament (NF), C) CSF myelin basic protein (MBP) and NF, and D) CSF CXCL13 and MBP in subjects with MS, neuromyelitis optica (NMO), other inflammatory conditions (OIC), and noninflammatory controls (NIC). No correlations were found between CSF CXCL13 and serum CXCL13 (A) or MBP (D).

254x190mm (96 x 96 DPI)

eFigure 1



eFigure 1. CSF biomarker in neuroinflammatory conditions.

A) CSF neurofilament (NF) and D) myelin basic protein (MBP) in subjects with multiple sclerosis (MS), neuromyelitis optica (NMO), other inflammatory neurological conditions (OIC), and noninflammatory controls (NIC). Medians are indicated. CXCL13 correlates with C) CSF protein and D) number of oligoclonal bands (OCB) across patient groups (r_s; solid lines). Disability, as assessed using the expanded disability status scale (EDSS), correlated with E) CSF protein and F) number of white blood cells (WBC). Note that logarithmic scales were sometimes used to better demonstrate values.

eFigure 2



eFigure 2. Biomarker correlations.

Correlations between A) CXCL13 in CSF and serum, B) CSF CXL13 and CSF neurofilament (NF), C) CSF myelin basic protein (MBP) and NF, and D) CSF CXCL13 and MBP in subjects with MS, neuromyelitis optica (NMO), other inflammatory conditions (OIC), and noninflammatory controls (NIC). No correlations were found between CSF CXCL13 and serum CXCL13 (A) or MBP (D).